Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure
DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.
Projectdetails
Introduction
The objective of DISSECT-HF is to generate engineered heart tissue (EHT) with the use of human induced pluripotent stem cells (hiPSC) from specific forms of heart failure (HF). It focuses on three etiologies of HF with a clear trigger and a large inter-individual susceptibility: pregnancy-induced HF, anthracycline cardiotoxicity, and PLN cardiomyopathy. The aim is to unravel common pathophysiological mechanisms involved in the development of HF.
Rationale
The rationale for this project includes:
- Better understanding of molecular pathways leading to HF and knowledge about inter-individual susceptibility is needed to improve treatment.
- For detection of changes on a molecular level, cardiac tissue is needed.
- Using innovative experimental approaches, such as dynamic loaded EHT (dyn-EHT), patient-specific cells, unbiased target finding, and deep phenotyping, I will dissect common disease pathways in the development of HF.
Specific Objectives
The specific objectives of the project are:
- Construction of dyn-EHT from patient-specific hiPSC-derived cardiomyocytes, endothelial cells, and fibroblasts.
- Generation and deep-phenotyping of dyn-EHT from: A) Females with pregnancy-induced HF (susceptible) and siblings with a normal pregnancy (resilience). B) Cancer patients with severe HF after anthracyclines (susceptibility) and patients who could resist high-dose anthracyclines (resilience). C) Patients with an early PLN cardiomyopathy phenotype (susceptible) versus elderly asymptomatic PLN mutation carriers (resilience).
- Identify overlapping and diverse factors.
- Validate discoveries and apply in unique human cohorts with data on incident HF.
Workpackages
The workpackages for this project include:
- WP1: Optimize construction of dyn-EHT from patient-specific hiPSC.
- WP2: Phenotyping of dyn-EHT from the three HF etiologies focusing on susceptibility and resilience.
- WP3: Explore the transcriptome and proteome and apply a systems biology approach.
- WP4: Validate results and explore human relevance in a large cohort with unique phenotyping.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.998.775 |
Totale projectbegroting | € 1.998.775 |
Tijdlijn
Startdatum | 1-11-2022 |
Einddatum | 31-10-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ACADEMISCH ZIEKENHUIS GRONINGENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTsG-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease. | ERC Starting... | € 1.497.351 | 2022 | Details |
DeCiphering Systemic Diurnal MetabOlism and EnDocrinE Signaling in HEART FailureCODE-HEART aims to uncover how heart failure alters systemic metabolic rhythms through interorgan communication, enhancing understanding of its complex multiorgan nature. | ERC Starting... | € 1.721.063 | 2025 | Details |
Programming the EPIcardium to CURE broken heartsEPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques. | ERC Advanced... | € 2.499.999 | 2024 | Details |
Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular DiseaseThe 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health. | ERC Starting... | € 1.496.395 | 2022 | Details |
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs
G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.
DeCiphering Systemic Diurnal MetabOlism and EnDocrinE Signaling in HEART Failure
CODE-HEART aims to uncover how heart failure alters systemic metabolic rhythms through interorgan communication, enhancing understanding of its complex multiorgan nature.
Programming the EPIcardium to CURE broken hearts
EPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques.
Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease
The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients. | EIC Pathfinder | € 4.137.668 | 2023 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.
The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.